STOCKHOLM, March 30, 2026 /PRNewswire/ -- Sobi® (STO: SOBI) today announced that the European Medicines Agency (EMA) has validated an indication extension application for Tryngolza® (olezarsen) for the treatment of adult patients with severe hypertriglyceridemia (sHTG) ≥880 mg/dL (≥10 mmol/L). Patients with elevated triglyceride levels have substantially higher risks of all-cause mortality, atherosclerotic cardiovascular events, and acute pancreatitis[1]. The submission is supported by results f

In a separate announcement made today, the Company also secured A$83 million in private placement funding to support growth initiatives, including European expansion. MELBOURNE, Australia, March 30, 2026 /PRNewswire/ -- 4DMedical Limited (ASX:4DX), the global leader in cardiothoracic imaging software, announces that its latest imaging technology, CT:VQ™ has received CE Mark certification for commercial use in the European Union. 4DMedical will quickly launch commercial deployment of CT:VQ acro

SHANGHAI, March 30, 2026 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced that it has won "Biologics CDMO of the Year" (Large CDMOs) in the 2026 CDMO Leadership Awards. The company has also been recognized for excellence across multiple categories for "Large CDMO Biologic", including "Best Scaling Support", "Best Analytical Services", "Best Overall Staff", and "Best Project Management". Thes

AUCKLAND, New Zealand, March 29, 2026 /PRNewswire/ -- Aroa Biosurgery Limited today announced completion of its randomised controlled trial (RCT) evaluating Symphony, with a preliminary study read-out indicating the trial achieved its primary endpoint. Symphony is AROA's Cellular, Acellular and Matrix-like Product (CAMP), or skin substitute, designed for the treatment of hard-to-heal wounds, including diabetic foot ulcers (DFUs) and venous leg ulcers. The product combines multiple layers of AROA

AI-driven collaboration includes an exclusive worldwide license for a portfolio of programs spanning multiple therapeutic areas. CAMBRIDGE, Mass., March 29, 2026 /PRNewswire/ -- Insilico Medicine ("Insilico", HKEX: 3696), a clinical-stage biotechnology company powered by generative artificial intelligence (AI) and automation, today announced a drug discovery collaboration with Eli Lilly and Company ("Lilly") that uses Insilico's AI engine to accelerate the discovery and development of novel ther

MALMÖ, SE / ACCESS Newswire / March 27, 2026 / Ascelia Pharma (STO:ACE), a biotech focused on improving the life of people living with rare cancer conditions, today announced that an abstract with an evaluation of the detection of focal liver lesions with Orviglance contrast agent from two phase 2 studies has been accepted for oral presentation at the European Society of Gastrointestinal and Abdominal Radiology (ESGAR) Annual Meeting, taking place 9-12 June in Montpellier, France. The abstrac

iStock, francescoch Accumulating scientific evidence and industry interest from Eli Lilly, Altimmune and startup Baseline Therapeutics is driving further research on the therapeutic potential of GLP-1 receptor agonists in treating substance use disorders. While alcohol use disorder affects nearly 30 million people in the U.S. alone, only three drugs are approved by the FDA to treat the condition, compared to dozens for diabetes and hundreds for cancer. Multiple companies are now looking to end

Researchers from Hong Kong are developing a clinical-grade ophthalmic AI co-pilot system that not only assists doctors in diagnosing diseases but also supports treatment planning and follow-up management. The team at Hong Kong Polytechnic University (PolyU) have developed a prototype AI-enabled system – dubbed EyeAgent 1.0 – based on multimodal data, including clinical texts and images, that reportedly can identify about 260 ophthalmic conditions. Following pilots across the city and mainland Ch

LONDON, March 29, 2026 /PRNewswire/ -- Smartee Denti-Technology hosted a specialized clinical conference at the London Heathrow Marriott Hotel on March 21, gathering over 50 prominent dental professionals. The event focused on advancing Smartee's Mandibular Advancement Repositioning Technology (MART) applied in the treatment of Class II malocclusion, featuring collaborative lectures by Dr. Jingting Lu (Shanghai Taikang Bybo Dental Group) and Dr. Pratik Sharma, Consultant Orthodontist and Academ

This partnership represents a vital strategic step toward reinforcing our role in supporting the healthcare sector through collaboration with a leading provider of eye care services. ” — Dr. Tarek Hosni, CEO of Jamjoom Pharma JEDDAH, SAUDI ARABIA, March 29, 2026 / EINPresswire.com / -- In a move reflecting their shared commitment to advancing the healthcare sector and elevating the quality of medical services, Jamjoom Pharma, one of the fastest-growing pharmaceutical companies in the Middle East